- $3.25bn
- $2.94bn
- $460.16m
HK-listed Zai Lab hits 2-year peak on higher product revenue
Brief: Zai Lab Posts FY Net Loss $257.1 Million
Zai Lab Ltd expected to post a loss of 7 cents a share - Earnings Preview
Brief: Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
Brief: Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
Brief: Zai Lab, Vertex Sign Strategic Agreement To Develop, Commercialize Povetacicept In Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region And Singapore
Brief: Zai Lab Ltd Zai Lab Shanghai Entered Into Working Capital Loan Contract With Bocom Regarding Revolving Credit Facility Of Up To Rmb300 Million
Brief: Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO®
Brief: Zai Lab Announces Public Offering Of 7.8 Million American Depositary Shares At A Price Of Us$25.50 Per ADS
US-listed shares of Zai Lab slide after commencing $200 mln stock offering
Brief: Zai Lab Ltd Commenced Underwritten Public Offering Of $200 Million Of Adss
Zai Lab Ltd reports results for the quarter - Earnings Summary
Zai Lab Ltd expected to post a loss of 8 cents a share - Earnings Preview
Brief: Zai Lab Reports Positive Topline Data From Phase 3 Bridging Trial Evaluating Karxt For The Treatment Of Schizophrenia In China
Zai Lab gains on early data from lung cancer drug study
Brief: Zai Lab To Present Data From Phase 1 Trial Of ZL-1310, For DLL3+ Solid Tumors
Zai Lab Ltd expected to post a loss of 8 cents a share - Earnings Preview
Brief: Zai Lab And Argenx Announce Approval Of Efgartigimod Alfa Injection For Generalized Myasthenia Gravis In China
Brief: JPMorgan Chase & Co's Long Position In Zai Lab Increases To 13.11%- HKEX